BRNS Projected Dividend Yield
Sponsored ADS/Barinthus Biotherapeutics plc ( NASDAQ : BRNS )Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases and autoimmunity. Its pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells and guide them towards a healthy balance. It is focused on developing two key product candidates that harness its viral vector and synthetic platform technologies. 21 YEAR PERFORMANCE RESULTS |
BRNS Dividend History Detail BRNS Dividend News BRNS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |